» Articles » PMID: 24325278

Bioactive Glass BAG-S53P4 for the Adjunctive Treatment of Chronic Osteomyelitis of the Long Bones: an in Vitro and Prospective Clinical Study

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2013 Dec 12
PMID 24325278
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis.

Methods: In vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic side effects connected with the BAG use.

Results: In vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after 24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed further surgical procedures. BAG-S53P4 was generally well tolerated.

Conclusions: The in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics.

Trial Registration: Deutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332.

Citing Articles

Nano-scaffold-based delivery systems of antimicrobial agents in the treatment of osteomyelitis ; a narrative review.

Yekani M, Dizaj S, Sharifi S, Sedaghat H, Saffari M, Memar M Heliyon. 2024; 10(21):e38392.

PMID: 39559197 PMC: 11570522. DOI: 10.1016/j.heliyon.2024.e38392.


Antimicrobial Biomaterials Based on Physical and Physicochemical Action.

Nowotnick A, Xi Z, Jin Z, Khalatbarizamanpoor S, Brauer D, Loffler B Adv Healthc Mater. 2024; 13(32):e2402001.

PMID: 39301968 PMC: 11670291. DOI: 10.1002/adhm.202402001.


Quantitative study of early-stage transient bacterial adhesion to bioactive glass and glass ceramics: atomic force microscopic observations.

Gour S, Mukherjee A, Balani K, Dhami N Sci Rep. 2024; 14(1):20336.

PMID: 39223136 PMC: 11369109. DOI: 10.1038/s41598-024-67716-0.


Current application and future perspectives of antimicrobial degradable bone substitutes for chronic osteomyelitis.

Jiang C, Zhu G, Liu Q Front Bioeng Biotechnol. 2024; 12:1375266.

PMID: 38600942 PMC: 11004352. DOI: 10.3389/fbioe.2024.1375266.


Use of Autologous Bone Graft with Bioactive Glass as a Bone Substitute in the Treatment of Large-Sized Bone Defects of the Femur and Tibia.

Findeisen S, Grafe N, Schwilk M, Ferbert T, Helbig L, Haubruck P J Pers Med. 2023; 13(12).

PMID: 38138871 PMC: 10744955. DOI: 10.3390/jpm13121644.


References
1.
Gordon L, Chiu E . Treatment of infected non-unions and segmental defects of the tibia with staged microvascular muscle transplantation and bone-grafting. J Bone Joint Surg Am. 1988; 70(3):377-86. View

2.
Ballo A, Lassila L, Vallittu P, Narhi T . Load bearing capacity of bone anchored fiber-reinforced composite device. J Mater Sci Mater Med. 2007; 18(10):2025-31. DOI: 10.1007/s10856-007-3159-6. View

3.
Munukka E, Lepparanta O, Korkeamaki M, Vaahtio M, Peltola T, Zhang D . Bactericidal effects of bioactive glasses on clinically important aerobic bacteria. J Mater Sci Mater Med. 2007; 19(1):27-32. DOI: 10.1007/s10856-007-3143-1. View

4.
McPherson E, Woodson C, Holtom P, Roidis N, Shufelt C, Patzakis M . Periprosthetic total hip infection: outcomes using a staging system. Clin Orthop Relat Res. 2002; (403):8-15. View

5.
Silvola J . Mastoidectomy cavity obliteration with bioactive glass: a pilot study. Otolaryngol Head Neck Surg. 2012; 147(1):119-26. DOI: 10.1177/0194599812438168. View